Pharmaceutical Analytical Testing Outsourcing Market to Hit USD 15.8 Billion by 2032

The pharmaceutical analytical testing outsourcing market is estimated to register an 8% CAGR between 2024 and 2032. The increasing complexity of pharmaceutical products and stringent regulatory requirements necessitate comprehensive analytical testing throughout the drug development and manufacturing.

Outsourcing analytical testing services enables pharmaceutical companies to access specialized expertise, advanced technologies, and state-of-the-art facilities for streamlining operations and reducing time-to-market. For instance, in November 2023, RSSL, a CRO (contract research organization) for food and pharmaceuticals, inaugurated its state-of-the-art analytical testing facility to fulfill increased client requirements in the life science, healthcare, food, and consumer goods industries.

The growing trend of outsourcing non-core activities to focus on core competencies is driving the adoption of pharmaceutical analytical testing outsourcing market services. By outsourcing analytical testing tasks to third-party service providers, pharmaceutical companies are allocating resources more strategically, prioritizing R&D initiatives, and accelerating innovation in drug development, creating opportunities for market growth.

The pharmaceutical analytical testing outsourcing market is classified based on service, product type, end-user, and region.

The industry size from the additives product type segment is projected to witness an 8.4% CAGR through 2032. The increasing complexity and diversity of additives used in pharmaceutical formulations necessitate specialized analytical testing to ensure product quality, safety, and compliance with regulatory standards. Outsourcing analytical testing services allows pharmaceutical companies to access expertise in additive analysis, including identification, quantification, and characterization of additives, without the need for significant investment in specialized equipment and personnel training.

The biopharmaceutical companies end-user segment in the pharmaceutical analytical testing outsourcing market is anticipated to observe an 8.4% CAGR during 2024-2032. The rising risks of biopharmaceutical products, including biologics, biosimilars, and gene therapies, require specialized analytical testing to ensure product quality, safety, and efficacy. Outsourcing partners also offer a comprehensive range of analytical testing capabilities tailored to the unique requirements of biopharmaceuticals, including cell-based assays, purity assessments, and glycan analysis.

The pharmaceutical analytical testing outsourcing market in Asia Pacific will record an 8.4% growth rate over 2024-2032, attributed to the burgeoning pharmaceutical sector and increasing investments in R&D activities. Domestic and multinational pharmaceutical companies' adoption of contract research and manufacturing services in the region has significantly risen. Growing regulatory harmonization efforts and increasing acceptance of outsourcing as a strategic business model in the pharmaceutical space will stimulate regional industry growth.

Source: https://www.gminsights.com/industry-analysis/pharmaceutical-analytical-testing-outsourcing-market